中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.034 seconds)

    난소암 특이적 후성학적 메틸화 마커 검출용 조성물 및 검출방법
    41.
    发明授权
    난소암 특이적 후성학적 메틸화 마커 검출용 조성물 및 검출방법 有权
    用于检测卵巢癌特异性甲基化标记物的组合物及其检测方法

    公开(公告)号：KR101597807B1

    公开(公告)日：2016-02-25

    申请号：KR1020150142991

    申请日：2015-10-13

    Applicant: 이화여자대학교 산학협력단

    Inventor： 안정혁

    IPC: C12Q1/68

    Abstract: 본발명은 H1F0(H1 histone family, member 0) 유전자프로모터의 CpG 부위의메틸화수준을검출함으로써, 난소암환자의백금기반의항암제치료반응성을예측하기위한조성물, 키트및 방법에관한것이다.

    Abstract translation: 本发明涉及通过检测H1组蛋白家族的启动子上的CpG区甲基化水平的成员0（H1F0）来预测基于铂的抗癌药物治疗卵巢癌患者的反应性的组合物， 基因。 本发明还涉及试剂盒及其方法。 为此，本发明的组合物包含用于测量H1F0基因启动子上CpG区甲基化水平的制剂。

    NUPR1 유전자 프로모터의 CpG 메틸화 변화를 이용한 모야모야병 진단용 조성물 및 이의 이용
    45.
    发明授权
    NUPR1 유전자 프로모터의 CpG 메틸화 변화를 이용한 모야모야병 진단용 조성물 및 이의 이용 有权
    用于使用NUPR1基因的启动子区域中的CpG甲基化状态诊断莫亚莫病的组合物及其用途

    公开(公告)号：KR101493044B1

    公开(公告)日：2015-02-16

    申请号：KR1020140090467

    申请日：2014-07-17

    Applicant: 이화여자대학교 산학협력단 ,  서울대학교산학협력단

    Inventor： 안정혁 ,  성혜윤 ,  김승기 ,  이지연

    IPC: C12Q1/68

    CPC classification number: C12Q1/6844

    Abstract: The present invention relates to a composition, a kit, and a method for diagnosing moyamoya disease by detecting methylation status of a CpG domain of a gene. The present invention relates to a technique of diagnosing moyamoya disease using DNA methylation changes of a gene. Provided in the present invention is a technique of diagnosing moyamoya disease by using the level of methylation of genes as a biomarker based on the discovery that a specific CpG domain of a gene is methylated in an endothelial progenitor cell (EPC) of a patient having moyamoya disease in the specifically low level.

    Abstract translation: 本发明涉及通过检测基因的CpG结构域的甲基化状态来诊断莫亚莫病的组合物，试剂盒和方法。 本发明涉及使用基因的DNA甲基化变化来诊断莫亚莫病的技术。 本发明提供了一种通过使用基因的甲基化水平作为生物标志物来诊断莫亚莫病的技术，其基于在具有moyamoya的患者的内皮祖细胞（EPC）中基因的特定CpG结构域被甲基化的发现 疾病特别低水平。

    ＧＡＢＲＰ 유전자 프로모터의 ＣｐＧ 메틸화 변화를 이용한 전이성 난소암 진단용 조성물 및 이의 이용
    48.
    发明授权
    ＧＡＢＲＰ 유전자 프로모터의 ＣｐＧ 메틸화 변화를 이용한 전이성 난소암 진단용 조성물 및 이의 이용 有权
    用GABRP基因启动子区域中CPG甲基化状态诊断卵巢癌的分子特征的组合物及其用途

    公开(公告)号：KR101275268B1

    公开(公告)日：2013-06-17

    申请号：KR1020130022244

    申请日：2013-02-28

    Applicant: 이화여자대학교 산학협력단

    Inventor： 안정혁 ,  성혜윤 ,  주웅

    IPC: C12Q1/68 ,  G01N33/574 ,  G01N33/48

    CPC classification number: C12Q1/6886 ,  C12Q1/6897 ,  C12Q2600/154 ,  G01N33/48 ,  G01N33/57449

    Abstract: PURPOSE: A composition for diagnosing metastatic ovarian cancer using CpG methylation change of a GABRP(gamma-aminobutyric acid receptor pi subunit) gene promoter is provided to measure methylation levels of a certain gene promoter site of genome DNA collected from a patient's sample, and to develop a diagnostic kit. CONSTITUTION: A composition for diagnosing or predicting ovarian cancer metastasis contains an agent for measuring methylation levels of CpG site of a GABRP gene promoter. The agent contains: a compound which modifies non-methylated cytosine or a methylation-sensitive restriction enzyme; a primer which is specific to a methylated sequence of the GABRP gene promoter; and a primer which is specific to a non-methylated sequence of the GABRP gene promoter. A method for providing information for diagnosing ovarian cancer metastasis or the risk of metastasis comprises: measuring methylation levels of a CpG site of the GABRP gene promoter from a patient's sample; and a step of comparing the methylation level of the GABRP gene promoter with a control group.

    Abstract translation: 目的：提供用于诊断转移性卵巢癌的组合物，其使用GABRP（γ-氨基丁酸受体pi亚基）基因启动子的CpG甲基化变化来测量从患者样品收集的基因组DNA的某个基因启动子位点的甲基化水平，并且 开发诊断试剂盒。 构成：用于诊断或预测卵巢癌转移的组合物含有用于测量GABRP基因启动子的CpG位点的甲基化水平的试剂。 该试剂含有：修饰非甲基化胞嘧啶或甲基化敏感性限制酶的化合物; 对GABRP基因启动子的甲基化序列特异的引物; 以及对GABRP基因启动子的非甲基化序列特异的引物。 提供用于诊断卵巢癌转移或转移风险的信息的方法包括：测量来自患者样品的GABRP基因启动子的CpG位点的甲基化水平; 以及将GABRP基因启动子的甲基化水平与对照组进行比较的步骤。

    ＡＧＲ２ 유전자 프로모터의 ＣｐＧ 메틸화 변화를 이용한 전이성 난소암 진단용 조성물 및 이의 이용
    49.
    发明授权
    ＡＧＲ２ 유전자 프로모터의 ＣｐＧ 메틸화 변화를 이용한 전이성 난소암 진단용 조성물 및 이의 이용 有权
    用于在AGR2基因的启动子区域使用CPG甲基化状态诊断卵巢癌的分子特征的组合物及其用途

    公开(公告)号：KR101275266B1

    公开(公告)日：2013-06-17

    申请号：KR1020130022240

    申请日：2013-02-28

    Applicant: 이화여자대학교 산학협력단

    Inventor： 안정혁 ,  성혜윤 ,  주웅

    IPC: C12Q1/68 ,  G01N33/574 ,  G01N33/48

    CPC classification number: C12Q1/6886 ,  C12Q1/6897 ,  C12Q2600/154 ,  G01N33/48 ,  G01N33/57449

    Abstract: PURPOSE: A composition for diagnosing metastatic ovarian cancer using CpG methylation of an AGR2(anterior gradient-2) gene promoter, and a use thereof are provided to quickly diagnose the risk of ovarian cancer metastasis by measuring the methylation of a certain gene promoter site of genome DNA isolated from a patient's sample by MSP(Methylation-Specific PCR), and to develop a convenient diagnostic kit with high accuracy. CONSTITUTION: A composition for diagnosing ovarian cancer metastasis or predicting the risk of metastasis contains an agent which measures methylation levels of a CpG site of an AGR2 gene promoter. The agent contains: a compound which changes non-methylated cytosine or a methylation-sensitive restriction enzyme; a primer which is specific to a methylated sequence of an AGR2 gene promoter; and a primer which is specific to a non-methylated sequence of an AGR2 gene promoter. A method for providing information for diagnosing ovarian cancer or predicting metastasis risk comprises: a step of measuring the methylation level of the CpG site of the AGR2 gene promoter from a patient's sample, who is suspected to have ovarian cancer metastasis; and a step of comparing the methylation level of the AGR2 gene promoter of the sample with a control group of primary ovarian cancer.

    Abstract translation: 目的：使用AGR2（前向梯度-2）基因启动子的CpG甲基化诊断转移性卵巢癌的组合物及其用途，通过测量某种基因启动子位点的甲基化来快速诊断卵巢癌转移的风险 通过MSP（甲基化特异性PCR）从患者样品中分离的基因组DNA，并开发出具有高精度的方便的诊断试剂盒。 构成：用于诊断卵巢癌转移或预测转移风险的组合物含有测量AGR2基因启动子的CpG位点的甲基化水平的试剂。 该试剂含有：改变非甲基化胞嘧啶或甲基化敏感性限制酶的化合物; AGR2基因启动子的甲基化序列特异的引物; 以及对AGR2基因启动子的非甲基化序列特异的引物。 提供用于诊断卵巢癌或预测转移风险的信息的方法包括：测量患者样品中怀疑患有卵巢癌转移的AGR2基因启动子的CpG位点的甲基化水平的步骤; 以及将样品的AGR2基因启动子的甲基化水平与原发性卵巢癌对照组进行比较的步骤。

Patent Agency Ranking